The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...

Cassava Sciences (SAVA) stock gains as company strikes consulting agreement with former CEO Remi Barbier. Read more here.

Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...